Welcome to our dedicated page for Polypid Ltd. SEC filings (Ticker: PYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PolyPid Ltd. (Nasdaq: PYPD) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer. PolyPid files annual reports on Form 20-F and frequent Form 6-K current reports, which provide detailed information on its clinical, regulatory, financial and corporate developments as a late-stage biopharma company.
Recent Form 6-K filings incorporate press releases on key milestones for D-PLEX100, PolyPid’s lead product candidate for the prevention of abdominal colorectal surgical site infections. These filings include reports of positive Phase 3 SHIELD II trial results, positive FDA pre-NDA meeting minutes supporting a New Drug Application submission, and the granting of Breakthrough Therapy designation. They also capture updates on the company’s regulatory strategy, such as the FDA’s agreement to a rolling NDA review.
PolyPid’s SEC reports further document manufacturing and quality milestones, including the successful completion of a Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health under the EU-Israel ACAA framework, which the company states confirms that its facility meets standards required for commercial production in the European market. Other 6-Ks address corporate governance matters, such as changes in board leadership, executive appointments, shareholder meeting outcomes and compensation policy approvals.
Financial information is regularly furnished through interim condensed consolidated financial statements and management’s discussion and analysis, attached as exhibits to Form 6-K. Additional filings describe capital-raising arrangements, including a Sales Agreement for the issuance and sale of ordinary shares and subsequent increases to the maximum aggregate offering price.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the main points of each document, helping readers quickly understand the significance of PolyPid’s 20-F annual reports, 6-K current reports and other registered offerings without reading every line of the underlying SEC text.
PolyPid Ltd. director Jacobovitz Yitzchak Shlomo has filed an initial Form 3, which is the baseline disclosure of his ownership in the company as a reporting insider. The filing shows no recent stock purchases, sales, or other transactions, and contains no derivative holdings.
PolyPid Ltd. director Robert Benjamin Stein reported his existing holdings of stock options to purchase Ordinary Shares. These options cover individual blocks such as 312 shares at an exercise price of 11.4000 per share expiring on 2033-05-05 and 6,500 shares at 4.2400 per share expiring on 2034-07-02. Another grant for 14,440 underlying shares has an exercise price of 2.6700 per share and expires on 2035-06-25, with vesting on a quarterly basis through 2029. Several earlier grants are already fully vested, reflecting established equity-based compensation rather than new market transactions.
PolyPid Ltd. has begun submitting a New Drug Application to the U.S. FDA for its lead product, D-PLEX₁₀₀, to prevent surgical site infections in patients undergoing colorectal surgery. The NDA is being filed under Fast Track designation, allowing a rolling review, and the first Chemistry, Manufacturing and Controls and nonclinical modules have been submitted, with the clinical section expected in the second quarter of 2026.
D-PLEX₁₀₀ uses PolyPid’s Kynatrix delivery technology to release the antibiotic doxycycline directly at the surgical site over 30 days. In the Phase 3 SHIELD II trial, it achieved a statistically significant 60% relative risk reduction in infection rates after abdominal colorectal surgery and has received Breakthrough Therapy Designation from the FDA. PolyPid is also advancing negotiations for a U.S. commercialization partnership.
PolyPid Ltd. executive Ori Warshavsky, Chief Operating Officer – US, reports his direct holdings of company equity. He holds several employee stock options to buy Ordinary Shares at exercise prices ranging from 2.6700 to 23.0700 per share, with expiration dates from 2031-08-09 through 2035-05-12.
These option grants vest on various quarterly schedules or are already fully vested, as described in the footnotes, and he also directly holds 267 Ordinary Shares.
PolyPid Ltd. director Dror-Darwish Nir reported existing option holdings in a Form 3. The filing lists six stock option grants over Ordinary Shares, with exercise prices ranging from 2.6700 to 23.0700 and expiration dates between 2030 and 2036. Footnotes state that most grants are already fully vested, while one grant made on June 25, 2025 vests quarterly through May 12, 2029.
PolyPid Ltd. Chief Financial Officer Jonathan Missulawin filed an initial ownership report listing multiple employee stock options over Ordinary Shares. These options cover various blocks of shares, including 64,500 underlying shares at an exercise price of 4.6400 and 42,000 underlying shares at 2.6700, with expirations ranging from 2027 to 2035. The filing records existing derivative holdings and does not show any stock purchases or sales.
PolyPid Ltd. director Barenholz Yechezkel reports his initial holdings in a Form 3. The filing shows direct ownership of 2,760 Ordinary Shares and several stock option awards over Ordinary Shares, with exercise prices ranging from $2.6700 to $23.0700 and expirations from 2031 to 2035. Footnotes explain that earlier grants are already fully vested, while a June 25, 2025 grant vests quarterly through May 12, 2029.
PolyPid Ltd. director Joseph BenAmram has reported his initial derivative holdings in company stock options. The Form 3 shows three stock option grants over ordinary shares with different exercise prices and vesting schedules. One grant covers 625 underlying shares at an exercise price of $11.4000 per share, expiring on May 8, 2033, and vests quarterly until May 8, 2026. A second grant covers 6,500 underlying shares at an exercise price of $4.2400, expiring on July 2, 2034, which was fully vested as of July 2, 2025. The third grant covers 14,440 underlying shares at an exercise price of $2.6700, expiring on June 25, 2035, and vests on a quarterly basis beginning May 12, 2025 until May 12, 2029. The filing lists these as direct holdings and does not show any new purchases or sales, only existing option positions.
PolyPid Ltd. director Story Brooke reported an initial holding of stock options on Ordinary Shares. The options cover 17,456 underlying Ordinary Shares at an exercise price of $4.01 per share and expire on February 4, 2036. According to the footnote, these options were granted on February 4, 2026 and vest on a quarterly basis beginning December 11, 2025, continuing through December 11, 2029.
PolyPid Ltd. director Krinsky Itzhak filed an initial ownership report showing a mix of ordinary shares and stock options. He directly holds 833 Ordinary Shares. He also holds several stock option awards over Ordinary Shares, including 6,500 shares at an exercise price of $4.2400 expiring on July 2, 2034 and 14,440 shares at $2.6700 expiring on June 25, 2035. Additional options cover smaller amounts of shares at exercise prices of $11.4000 and $23.0700 with expiration dates between 2029 and 2033. Footnotes state that most of these options are already fully vested, while the June 25, 2025 grant vests quarterly until May 12, 2029.